HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evidence-based efficacy of Kampo formulas in a model of non alcoholic fatty liver.

Abstract
Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1% cholesterol, or each of the five experimental treatments (Kampo formulas 1% keishibukuryogan [KBG], 1% orengedokuto [OGT], and 1% shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1% cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2'-deoxyguanosine (P < 0.05), hepatic alpha-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.
AuthorsMakoto Fujimoto, Koichi Tsuneyama, Mosaburo Kainuma, Nobuyasu Sekiya, Hirozo Goto, Yasuo Takano, Katsutoshi Terasawa, Carlo Selmi, M Eric Gershwin, Yutaka Shimada
JournalExperimental biology and medicine (Maywood, N.J.) (Exp Biol Med (Maywood)) Vol. 233 Issue 3 Pg. 328-37 (Mar 2008) ISSN: 1535-3702 [Print] England
PMID18296738 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adipokines
  • Alcohols
  • Biomarkers
  • Blood Glucose
  • Lipids
  • Transforming Growth Factor beta1
  • Hyaluronic Acid
Topics
  • Adipokines (blood)
  • Alcohols
  • Animals
  • Biomarkers
  • Blood Glucose (metabolism)
  • Body Weight (drug effects)
  • Chemistry, Pharmaceutical
  • Disease Models, Animal
  • Evidence-Based Medicine
  • Fatty Liver (blood, drug therapy, pathology)
  • Hyaluronic Acid (blood)
  • Lipids (blood)
  • Liver Cirrhosis (metabolism)
  • Male
  • Medicine, Kampo
  • Organ Size (drug effects)
  • Oxidative Stress
  • Rabbits
  • Transforming Growth Factor beta1 (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: